

PHARMANUTRA S.P.A.: THE BOARD OF DIRECTORS RESOLVES TO SUBMIT THE PROPOSAL TO AUTHORISE THE PURCHASE AND DISPOSAL OF TREASURY STOCK TO THE FORTHCOMING ORDINARY SHAREHOLDERS' MEETING

Pisa, 6th April 2020 - The Board of Directors of [PharmaNutra S.p.A.](http://PharmaNutra_S.p.A.) (Aim Italia-Ticker PHN), pharmaceutical company leader in the iron-based nutritional supplements sector ("**PharmaNutra**" or the "**Company**"), today decided to submit to the forthcoming Ordinary Shareholders' Meeting - scheduled for 27th April 2020 in first call (and if required 28th April 2020 in second call) – the **proposal to authorise the purchase and disposal of ordinary shares by PharmaNutra**, for the maximum term of 18 months permitted by law as of the date of the Ordinary Shareholders' Meeting resolution.

The request for authorisation to purchase and dispose of treasury stock is in order to give the Company **a strategic investment opportunity** for any purpose permitted by laws in force; including the use of shares as payment in extraordinary transactions, also the exchange of investments with other subjects, as part of transactions of interest to the Company, such as potential, further sector aggregations continually analysed and assessed by the Board of Directors.

PharmaNutra S.p.A. also reserves the right to allocate shares purchased to other purposes permitted by law in the interest of the Company, including their subsequent cancellation – within the terms and applying methods possibly decided by corporate bodies – and to dispose of them on AIM or outside that system.

The ordinary Shareholders' Meeting will be asked to authorise the purchase, also in several tranches, of a number of ordinary Company shares, with no indication of nominal value, for a **counter-value of maximum € 3,000,000**.

Furthermore, in compliance with Art. 2357, paragraph 1 of the Italian Civil Code, the purchase of shares must be within the limits of distributable profits and reserves available in the last financial statements approved (also interim) when the transaction takes place.

Purchase may be made for an amount that is no higher than the highest between the price of the last independent transaction and the price of the current highest independent offer in the trading seats where the purchase takes place. Without prejudice to the fact that the unit price may not be lower than

the minimum 20% and higher than maximum 10% of the reference price that the share recorded in the market session of the day prior to each single transaction.

The Ordinary Shareholders' Meeting will be called by notice published within legal and regulatory terms and methods. Besides the proposal to authorise the purchase and disposal of treasury stock, the forthcoming Shareholders' Meeting will be called on to approve the financial statements of PharmaNutra as at 31st December 2019 and allocation of period profit, and to appoint the Company's Board of Directors. The consolidated financial statements of the PharmaNutra Group as at 31st December 2019 will also be submitted to the Meeting.

Documents required by laws in force related to all items on the agenda of that Shareholders' meeting will be published, within terms and as established by laws in force, on the Company website www.pharmanutra.it, in the section "Investor Relations".

"In a period of important, unforeseeable market fluctuation that, at certain times, underestimates the share and does not reflect the true potential of PharmaNutra and its effective performances, our choice is to invest in the company with the conviction of who is well aware of its solidity and considerable improvement prospects", declares Roberto Lacorte, Vice President of the Group. "Trust supported by the last, positive financial statement figures, by the equally favourable sales figures for the first quarter 2020 and by the numerous agreements being finalised for distribution of our products abroad; and not to mention the acknowledgement of our patents in exceedingly important counties such as the United States and India".

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated with a wealth of scientific evidence, with 112 studies published involving more than 7000 subjects. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 140 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 34 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

PharmaNutra.it

For information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b
56122 Pisa
Tel. +39 050 7846500
investorrelation@pharmanutra.it
Internal Press Office
press@calabughi.com

**Nomad
CFO SIM S.p.A.**

Via dell'Annunciata, 23/4
20121 Milan
Tel. +39 02 303431
ecm@cfosim.com

**Press Office
Spriano Communication & Partners**

Via Santa Radegonda, 16
20121 Milan
Tel. +39 02 83635708

Matteo Russo
mrusso@sprianocommunication.com
Cristina Tronconi
ctronconi@sprianocommunication.com